First-in-class peptide drug based on IDDT platform technology

 

New drug development company.

​

REMEDI was established in 2020 and aimed to develop new drugs using the Intra-cellular Drug Delivery Technology (IDDT) platform. 

​

Cell penetrating peptides found based on IDDT platform can be attached to peptides, proteins, RNA, DNA, etc. to increase efficency and reduce toxicity.

​

All executives and employees will do their best to improve human life through effective and innovative drug development.

​​

​

Chanho Park      C.E.O.